UY34542A - ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. - Google Patents

?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.

Info

Publication number
UY34542A
UY34542A UY0001034542A UY34542A UY34542A UY 34542 A UY34542 A UY 34542A UY 0001034542 A UY0001034542 A UY 0001034542A UY 34542 A UY34542 A UY 34542A UY 34542 A UY34542 A UY 34542A
Authority
UY
Uruguay
Prior art keywords
fumagiline
phf
conjugates
derivatives
pharmaceutical formulations
Prior art date
Application number
UY0001034542A
Other languages
English (en)
Spanish (es)
Inventor
Akullian Laura
Liu Gui
Lowinger Timothy
Mcgillicuddy Dennis
Stevenson Cheri
John Van Duzer
Yin Mao
Yurkovetskiy Aleksandr
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of UY34542A publication Critical patent/UY34542A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
UY0001034542A 2011-12-23 2012-12-21 ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?. UY34542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580016P 2011-12-23 2011-12-23
US201261639654P 2012-04-27 2012-04-27

Publications (1)

Publication Number Publication Date
UY34542A true UY34542A (es) 2013-07-31

Family

ID=48669583

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034542A UY34542A (es) 2011-12-23 2012-12-21 ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.

Country Status (9)

Country Link
US (1) US20130189218A1 (https=)
EP (1) EP2794582A1 (https=)
JP (1) JP2015503635A (https=)
KR (1) KR20140121827A (https=)
CN (1) CN104024236A (https=)
IN (1) IN2014MN01488A (https=)
TW (1) TW201332574A (https=)
UY (1) UY34542A (https=)
WO (1) WO2013096901A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
JP2018506509A (ja) 2014-12-09 2018-03-08 アッヴィ・インコーポレイテッド 細胞透過性Bcl−xL阻害剤との抗体薬物コンジュゲート
KR20170093943A (ko) 2014-12-09 2017-08-16 애브비 인코포레이티드 낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
EP3383910A1 (en) 2015-11-30 2018-10-10 AbbVie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
AU2016365114A1 (en) 2015-11-30 2018-05-17 Abbvie Biotherapeutics Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
EP4094778B1 (en) 2016-06-03 2024-05-15 Novacyte Therapeutics Company.,LTD Polymer linkers and their uses
JP2019521975A (ja) 2016-06-08 2019-08-08 アッヴィ・インコーポレイテッド 抗egfr抗体薬物コンジュゲート
EP3469000A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗b7−h3抗体及び抗体薬物コンジュゲート
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
CN116173232A (zh) 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
EP3458479B1 (en) 2016-06-08 2020-11-04 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109563168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
BR112018075644A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
BR112018075639A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. conjugados de anticorpo fármaco anti-egfr
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
PL3817751T3 (pl) * 2018-07-03 2025-09-08 Fennec Pharmaceuticals, Inc. Postacie użytkowe bezwodnego tiosiarczanu sodu
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
AU2020327000A1 (en) 2019-08-08 2022-03-31 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
CN114786730A (zh) 2019-11-05 2022-07-22 再生元制药公司 N-端scFv多特异性结合分子
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
EP4114860A1 (en) 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc抗体およびその使用
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
AU2022339819A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
CA3235106A1 (en) * 2021-10-19 2023-04-27 Sixiang FAN Conjugate pharmaceutical preparation, preparation method therefor and use thereof______________
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP2217283A2 (en) * 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
WO2010138719A1 (en) * 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers

Also Published As

Publication number Publication date
KR20140121827A (ko) 2014-10-16
CN104024236A (zh) 2014-09-03
TW201332574A (zh) 2013-08-16
IN2014MN01488A (https=) 2015-04-17
WO2013096901A1 (en) 2013-06-27
WO2013096901A8 (en) 2014-08-07
EP2794582A1 (en) 2014-10-29
JP2015503635A (ja) 2015-02-02
US20130189218A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
MX2021001231A (es) Compuestos heterociclicos y sus usos.
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX2015003140A (es) Formulaciones de enzalutamida.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
GT201500069A (es) Piridinonas bicìclicas novedosas
ECSP16074478A (es) Compuestos novedosos
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
MX2015009479A (es) Compuestos y metodos para tratar infecciones bacterianas.
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
UY33976A (es) Derivados de pirazolo-pirimidina.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
UY34223A (es) Formulaciones de (trimetoxifenilamino)pirimidinilo nuevas
UY34023A (es) Derivados de fenil-isoxazol y procedimiento para la preparación de los mismos
BR112015009839A2 (pt) composição farmacêutica de tapentadol para administração parenteral

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020